EpiEndo receives €2.7m from the European Innovation Council Fund
EpiEndo Pharmaceuticals, an Icelandic clinical-stage biopharmaceutical company developing novel non-antibiotic macrolide therapeutics for the treatment of inflammatory disorders, announced last week that it was a recipient of a €2.7m convertible loan agreement from the European Innovation Council Fund.
The Fund was created by the European Commission last year, and
